factograf
EN
Sign in

rare neurodegenerative disease with amyotrophy and progressive paralysis

ALS

ALS

Amyotrophic lateral sclerosis (ALS), also called motor neuron disease, Lou Gehrig's disease or Charcot's disease, is a rare terminal neurodegenerative illness in which both upper and lower motor neurons, the cells controlling voluntary muscle movement, progressively die. It is the most common of the motor neuron diseases. Symptoms often begin with muscle stiffness, twitching, weakness and wasting, and the loss of motor neurons usually continues until a person can no longer eat, speak, move or breathe without mechanical support. At least half of those affected experience notable changes in thinking or behavior.

Types and causes

Affected neurons and muscles in ALS
Affected neurons and muscles in ALS
Classic ALS involves upper motor neurons in the brain and spinal cord (highlighted red) and lower motor neurons running from the spinal cord to the muscles (highlighted teal)
Classic ALS involves upper motor neurons in the brain and spinal cord (highlighted red) and lower motor neurons running from the spinal cord to the muscles (highlighted teal)
Illustration of the range of upper and lower motor neuron involvement in the two most common types of ALS (top row) and three of the most common rare subtypes (bottom row)
Illustration of the range of upper and lower motor neuron involvement in the two most common types of ALS (top row) and three of the most common rare subtypes (bottom row)
Figure showing ten proposed disease mechanisms for ALS and the genes associated with them
Figure showing ten proposed disease mechanisms for ALS and the genes associated with them
An axial FLAIR MRI of the brain, viewed from below, showing a small white region in the posterior internal capsule consistent with an ALS diagnosis
An axial FLAIR MRI of the brain, viewed from below, showing a small white region in the posterior internal capsule consistent with an ALS diagnosis
A person with late-stage ALS using assistive technology: a power wheelchair for movement, invasive ventilation for breathing, and an eye tracker with a computer for communication
A person with late-stage ALS using assistive technology: a power wheelchair for movement, invasive ventilation for breathing, and an eye tracker with a computer for communication
6 images

ALS is classified by which motor neurons are affected, which body region symptoms begin in, whether it is genetic, and the age of onset. Most cases, roughly 90 to 95 percent, have no known cause and are called sporadic. Genetic, autoimmune and environmental factors are thought to play a part. About 5 to 10 percent of cases have a known genetic origin and are often linked to family history, with mutations in the C9orf72 gene being the most common known genetic cause.

Treatment and outlook

Non-invasive ventilation supporting breathing through a face or nasal mask connected to a ventilator
Non-invasive ventilation supporting breathing through a face or nasal mask connected to a ventilator
A man with ALS communicates by pointing to letters and words with a head-mounted laser pointer on his glasses
A man with ALS communicates by pointing to letters and words with a head-mounted laser pointer on his glasses
A gastrostomy tube placed through the abdominal wall into the stomach
A gastrostomy tube placed through the abdominal wall into the stomach
Estimated prevalence of ALS in the United States by age group, 2012–2015
Estimated prevalence of ALS in the United States by age group, 2012–2015
French neurologist Jean-Martin Charcot coined the term amyotrophic lateral sclerosis in 1874
French neurologist Jean-Martin Charcot coined the term amyotrophic lateral sclerosis in 1874
American baseball player Lou Gehrig, after whom ALS is called Lou Gehrig's disease in some countries, especially the United States
American baseball player Lou Gehrig, after whom ALS is called Lou Gehrig's disease in some countries, especially the United States
6 images

There is currently no cure for ALS, so treatment aims to slow progression and ease symptoms. Two drugs approved by the US Food and Drug Administration, riluzole and edaravone, slow the disease. Non-invasive ventilation may improve both quality and length of life, while mechanical ventilation can prolong survival without halting progression. A feeding tube can help maintain nutrition. Death is usually caused by respiratory failure. The disease can affect people of any age but usually begins around 60, and average survival from onset is two to four years, though about 10 percent of those affected live beyond ten years.

In 12 languages

Редакція Factograf · Published October 14, 2026 · Partly based on Wikipedia, CC BY-SA 4.0 · Source article